Does current evidence justify prostate cancer screening in Europe?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Frankel S et al. (2003) Screening for prostate cancer. Lancet 361: 1122–1128

  2. 2

    Stanford JL et al. (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283: 354–360

  3. 3

    The UK National Screening Committee (NSC) []

  4. 4

    McGregor M et al. (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159: 1368–1372

  5. 5

    Draisma G et al. (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868–878

  6. 6

    Gann PH et al. (1995) A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289–294

  7. 7

    Hakama M et al. (2001) Validity of the prostate specific antigen test for prostate cancer screening: followup study with a bank of 21,000 sera in Finland. J Urol 166: 2189–2191

  8. 8

    Thompson IM et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350: 2239–2246

  9. 9

    Thompson IM et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66–70

  10. 10

    Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977–1984

  11. 11

    Oliver SE et al. (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355: 1788–1789

  12. 12

    Lu-Yao G et al. (2002) Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 325: 740

Download references

Author information

Correspondence to Richard M Martin.

Ethics declarations

Competing interests

Richard M Martin and Jenny Donovan are principal investigators on a randomized controlled trial of the potential population impact of PSA testing for prostate cancer in the UK (Comparison arm for ProtecT trial, CAP), funded by Cancer Research UK/UK Department of Health, and the NHS Health Technology Assessment Programme.

Rights and permissions

Reprints and Permissions

About this article

Further reading